Why carry out this study?

Respiratory syncytial virus (RSV) results in a substantial number of cases, complications, healthcare resource use, and deaths in older adults.

Two vaccines are now available in the United States for the prevention of RSV in adults aged 60 years and older. This study modeled the public health impact of vaccinating older adults in the United States with the adjuvanted RSVPreF3 vaccine. Vaccination was given once at the start of the analysis and the impact was assessed over 3 years.

What was learned from the study?

Assuming the same vaccination coverage as for influenza vaccines, adjuvanted RSVPreF3 vaccination was estimated to prevent nearly 3 million symptomatic RSV cases over 3 years, including over 1.5 million outpatient visits, over 200,000 hospitalizations, and nearly 17,000 deaths compared with no vaccination.

Vaccinating adults aged 60 years and older with the adjuvanted RSVPreF3 vaccine provides substantial public health benefits in the United States.